Latest Achievements
- Publication of collaborative research results demonstrating potential for use Aminex's PaBT approach for treatment of neuroblastoma (Samal, K.; Zhao, P.; Kendzicky, A.; Yco, L.P.; McClung, H.; Gerner, E.; Burns, M.; Bachmann, A.S.; Sholler, G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithing decarboxylase and polyamine transport. Accepted for publication in Int. J. Cancer, DOI: 10.1002/ijc.28139).
- Results from Phase I/II trial using PaBT™ for oral cancers in house cats has been published (see Skorupski, K. A., O'Brien, T. G., Guerrero, T., Rodriguez, C. O., and Burns, M. R. Phase I/II clinical trial of 2-difluoromethylornithine (DFMO) and a novel polyamine transport inhibitor for feline oral squamous cell carcinoma., Vet Comp Oncol. 2011, 9(4), 275-82).
- Development achievements including custom manufacturing of AMXT 1501, formulation and delivery testing and bioanalytical analysis method development have been achieved.
News
- Dr. Mark R. Burns, President & CEO presented Aminex's PaBT approach at the BIO 2013 Conference in Chicago. He spoke at the BIO Business Forum at 10:45am on Wednesday, April 24, 2013 in the Chicago Blackhawks Room.
- Publication of collaborative research results demonstrating potential for use Aminex's PaBT approach for treatment of neuroblastoma (Samal, K.; Zhao, P.; Kendzicky, A.; Yco, L.P.; McClung, H.; Gerner, E.; Burns, M.; Bachmann, A.S.; Sholler, G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithing decarboxylase and polyamine transport. Accepted for publication in Int. J. Cancer, DOI: 10.1002/ijc.28139).
- Dr. Mark R. Burns, President & CEO spoke at the Life Sciences Innovation Northwest (LSINW) Conference, held July 11 and 12, 2012 in Seattle.
- Reissue of Aminex's US Patent has been awarded.